Literature DB >> 28115504

Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality.

I Patel1, M Wungjiranirun2, T Theethira1, J Villafuerte-Galvez1, N Castillo1, M Akbari1, C D Alonso1, D A Leffler1, C P Kelly1.   

Abstract

OBJECTIVES: The objective of this study was to determine our institution's compliance with 2010 Society for Healthcare Epidemiology of America and IDSA Clostridium difficile infection (CDI) treatment guidelines and their respective outcomes.
METHODS: We collected clinical parameters, laboratory values, antibiotic therapy and clinical outcomes from the electronic medical records for all patients hospitalized at our institution with a diagnosis of CDI from December 2012 to November 2013. We specifically evaluated whether SHEA-IDSA treatment guidelines were followed and evaluated the associations between guideline adherence and severe outcomes including mortality.
RESULTS: We identified 230 patients with CDI meeting inclusion criteria during the study period. Of these, 124 (54%) were appropriately treated, 46 (20%) were under-treated and 60 (26%) were over-treated. All-cause 90 day mortality was 17.4% overall; 43.5% in the under-treated group versus 12.9% in those appropriately treated (P < 0.0001) and 10.9% in those appropriately treated plus over-treated (P < 0.0001). Similarly, 90 day mortality attributed to CDI was 21.7% in those under-treated versus 8.9% in those appropriately treated (P = 0.03) and 8.2% in those either appropriately treated or over-treated (P = 0.015). Severe-complicated CDI occurred in 46 patients. In this subgroup, there was a non-significant trend towards increased mortality in under-treated patients (56.7%) compared with appropriately treated patients (37.5%, P = 0.35). Under-treatment was also associated with a higher rate of CDI-related ICU transfer (17.4% versus 4.8% in those appropriately treated, P = 0.023).
CONCLUSIONS: Adherence to CDI treatment guidelines is associated with improved outcomes especially in those with severe disease. Increased emphasis on provision of appropriate, guideline-based CDI treatment appears warranted.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28115504      PMCID: PMC6074846          DOI: 10.1093/jac/dkw423

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

Review 1.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

2.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

Authors:  M P Bauer; E J Kuijper; J T van Dissel
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

Review 3.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

4.  Clostridium difficile and vancomycin-resistant enterococcus: the new nosocomial alliance.

Authors:  R D Poduval; R P Kamath; M Corpuz; E P Norkus; C S Pitchumoni
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  Deaths: final data for 2008.

Authors:  Arialdi M Miniño; Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek
Journal:  Natl Vital Stat Rep       Date:  2011-12-07

6.  Effect of treatment variation on outcomes in patients with Clostridium difficile.

Authors:  Adam T Brown; Charles F Seifert
Journal:  Am J Med       Date:  2014-05-23       Impact factor: 4.965

Review 7.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

8.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

9.  Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals.

Authors:  Becky A Miller; Luke F Chen; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

10.  The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

Authors:  Judith A O'Brien; Betsy J Lahue; J Jaime Caro; David M Davidson
Journal:  Infect Control Hosp Epidemiol       Date:  2007-10-03       Impact factor: 3.254

View more
  7 in total

1.  Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.

Authors:  Shannon A Novosad; Yi Mu; Lisa G Winston; Helen Johnston; Elizabeth Basiliere; Danyel M Olson; Monica M Farley; Andrew Revis; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Tory Whitten; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Valerie L S Ocampo; Corinne M Davis; Marion Kainer; Dale N Gerding; Alice Y Guh
Journal:  J Gen Intern Med       Date:  2019-11-25       Impact factor: 5.128

2.  Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.

Authors:  Natasa Popovic; Milos Korac; Zorica Nesic; Branko Milosevic; Aleksandar Urosevic; Djordje Jevtovic; Nikola Mitrovic; Aleksandar Markovic; Jelena Jordovic; Natasa Katanic; Aleksandra Barac; Ivana Milosevic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-03       Impact factor: 3.267

3.  Capsule Commentary on Novosad et al., Treatment of Clostridioides Difficile Infection and Non-compliance with Treatment Guidelines in Adults, 10 US Geographical Locations, 2013-2015.

Authors:  Kelly R Reveles
Journal:  J Gen Intern Med       Date:  2020-02       Impact factor: 5.128

4.  Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.

Authors:  K Kobayashi; N Sekiya; Y Ainoda; H Kurai; A Imamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-02       Impact factor: 3.267

5.  The effect of concomitant use of systemic antibiotics in patients with Clostridium difficile infection receiving metronidazole therapy.

Authors:  S J Jin; K H Seo; Y M Wi
Journal:  Epidemiol Infect       Date:  2018-03-01       Impact factor: 4.434

6.  Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study.

Authors:  Hsiu-Yin Chiang; Han-Chun Huang; Chih-Wei Chung; Yi-Chun Yeh; Yi-Chin Chen; Ni Tien; Hsiu-Shan Lin; Mao-Wang Ho; Chin-Chi Kuo
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-12       Impact factor: 4.887

7.  Treatment of Clostridium difficile infection in community teaching hospital: a retrospective study.

Authors:  Ali Elbeddini; Rachel Gerochi
Journal:  J Pharm Policy Pract       Date:  2021-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.